Premium
Malignant glioma: Who benefits from adjuvant chemotherapy?
Author(s) -
Deangelis Lisa M.,
Burger Peter C.,
Green Sylvan B.,
Cairncross J. Gregory
Publication year - 1998
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410440418
Subject(s) - glioma , adjuvant , chemotherapy , medicine , oncology , adjuvant chemotherapy , cancer research , cancer , breast cancer
We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long‐term survival regardless of prognostic factors. Pathological review revealed that oligodendrogliomas were overrepresented among long‐term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long‐term survival with chemotherapy is not explained by oligodendroglial tumors.